Who are PF-07820435's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PF-07321332 Dose 5, Paxlovid (Copackaged), Victrelis, Prezista, TIPRANAVIR, Lexiva.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pf-07820435.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

PF-07820435 — Competitive Intelligence Brief

PF-07820435 (pf-07820435) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor. Area: Oncology.

discontinued Protease inhibitor SARS-CoV-2 3CL protease (main protease) and/or cellular proteases in oncology indications Oncology Live · refreshed every 30 min

Target snapshot

PF-07820435 (pf-07820435) — Pfizer Inc.. PF-07820435 inhibits viral or cellular proteases to disrupt essential enzymatic processes required for viral replication or tumor cell survival.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PF-07820435 TARGET	pf-07820435	Pfizer Inc.	discontinued	Protease inhibitor	SARS-CoV-2 3CL protease (main protease) and/or cellular proteases in oncology indications
PF-07321332 Dose 5	pf-07321332-dose-5	Pfizer	marketed	Protease inhibitor	Main protease (MPro) of SARS-CoV-2	Pending regulatory approval
Paxlovid (Copackaged)	Nirmatrelvir	Pfizer	marketed	Antiviral protease inhibitor	SARS-CoV-2 main protease (Mpro, 3CLpro, nsp5 protease)	2023-01-01
Victrelis	BOCEPREVIR	Merck & Co.	marketed	Hepatitis C Virus NS3/4A Protease Inhibitor	Chymase	2011-01-01
Prezista	DARUNAVIR	Janssen Prods	marketed	Protease Inhibitor [EPC]	Multidrug resistance protein 1	2006-01-01
TIPRANAVIR	TIPRANAVIR		marketed	Protease Inhibitor [EPC]		2005-01-01
Lexiva	FOSAMPRENAVIR	GSK	marketed	Protease Inhibitor		2003-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2041-08-05 — Paxlovid (Copackaged) · 11351149 · US
2041-10-31 — Paxlovid (Copackaged) · 11541034 · US

Sponsor landscape (Protease inhibitor class)

Pfizer · 4 drugs in this class
French National Agency for Research on AIDS and Viral Hepatitis · 4 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class
Christopher J. McLeod · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Janssen R&D Ireland · 1 drug in this class
Janssen-Cilag International NV · 1 drug in this class
Johns Hopkins University · 1 drug in this class
Medical Research Council · 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PF-07820435 — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-07820435. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab